Inogen’s product portfolio, global reach and innovation pipeline with Yuwelding.com investment.
GOLTA, Calif.– Inch In-Home (NASDAQ. INGE), a medical technology company (NASADAQ), today announced that it has entered into a strategic partnership with the giant Yuwei. Treatment (Ted:) EQUIPMENT AND SUPPLY CO., Liwd. (002223.SZ), Internet Health Device (002223.SZ), International Home Health Device (002223.SZ), Comprehensive Portfolio of Respiratory Products
With the distribution of certain host products in the United States, the innovation portfolio of Inogens is expected to accelerate and accelerate the Inogen brand in R & Doben. Chinese market. In addition, Yule, representing a common equity interest of 9.9% on the part of the partner, is approximately $ 27.2 million, and the sounding of Onogen’s balance sheet is more pronounced.
The collaboration with Yuel is an important step in accelerating the development direction of Oyogen. We are accelerating our product portfolio, global growth, and government growth to capture new market opportunities, said Kevin Smith, President and Chief Executive Officer. This collaboration has enabled us to combine our commitment to delivering long-term value to our members with our vision to breathe in the vision of delivering access solutions for patients worldwide. We are confident that our partnership with Yuel will play a vital role in your continued success.
Alex Wu, Ill. Alex Wu added, Intigen is a leader in the augmented respiratory market and our strategic position is to provide both parties with the need to expand their geographic footprint in the world. We believe that Uweld Deogen Deogens’ innovation, commitment to developing and providing quality products, and making a meaningful difference in the lives of patients with off-the-shelf treatments. Together, Uell and Endogen aim to define the next generation of respiratory systems.
The cooperation agreement will be effective soon, it is expected to close in the first quarter of the first entertainment conditions related to the purchase of equity.
About Onogen
Inogen, Inc. (NASDAQ: Ingn) is a medical technology company providing innovative respiratory products for use in your home care setting. Health supports inpatient respiratory care developed for patients suffering from severe respiratory conditions. For patients, historical partners, host treatments to be widespread, and to be distributed widely, patients are given the opportunity to manage the impact of their disease.
For more information, please visit www.inogen.com.
Engine has been used, the website of the clothing relations, the ability to disclose public non-public information and will continue to be used in the way it has been used to comply with the disclosure obligations in the Regulation FDF.
About Yule
In the year Since its establishment in 1998, Utul has been at the forefront of providing cutting-edge medical equipment to enhance patient care and improve home healthcare worldwide. Yuweld (002223.SZ) is expected to reach US$ 100 million in revenue by 2023, and is focused on respiratory medicine, diabetes management, electronic assessment solutions, first aid solutions and rehabilitation.
With an unwavering commitment to clinical excellence, UWELL provides healthcare professionals with high-quality, medically reliable products that ensure they have access to certified professionals.
With 9 state-of-the-art R&D centers and 7 advanced manufacturing facilities in more than 100 countries, it supports more than 300,000 healthcare positions. Utool touches the lives of patients around the world by bringing user-friendly medical devices into the home.
Forward-looking statements
In the year In 1995, Conon’s future business plans, marketing plans, market opportunities, future press releases. Financial network, development strategies and expected operating results, are forward-looking statements. They are intended to identify such expressions as intentions, believes, expect, plans, plans, expect, expect, expect, expected, possible, possible and similar. Forward-looking statements are currently subject to a number of risks and uncertainties that may result in the benefits of the partnership with Nonel, uncertainty and uncertainty, the satisfaction of closing conditions for the purchase of securities in connection with the equity investment, the timing of the closing of the equity investment; receiving the products; competition The sales, marketing and distribution capabilities; Planned sales, marketing and research and development activities; and risks associated with international operations. For a detailed explanation of these risks that may affect Inogen’s business and financial performance, refer to the section of the annual report on the 10th day of 2023. For the calendar quarter is March 31, 2024 and in other filters with the blocking and exchange commission. These descriptions of the transmission speak only as of the date. Inogen disclaims any obligation to update these forward-looking statements unless required by law.
See the rule version on Scouway.com
Is@inogen.net
Source-Engineering, Inc.